Core Insights - Teladoc Health has launched enhancements to its 24/7 Care service, expanding its capabilities to address a broader spectrum of health needs and deliver more value in virtual urgent care visits [1][3] Service Enhancements - The enhanced 24/7 Care service allows Teladoc Health's care teams to treat a wider range of conditions, including back and joint pain, hair loss, sleep issues, and provides support for members with uncontrolled hypertension, diabetes, asthma, and COPD [4] - Care providers can now consult with board-certified specialists during visits, enabling quicker confirmation of care plans and addressing over 95% of member concerns in a single visit, thus avoiding unnecessary follow-ups and ER visits [5] - Integrated claims and Health Information Exchange (HIE) data allow care providers to identify gaps in care and promote preventive care, with 70% of members agreeing to take action on preventive care recommendations made during visits [6] Care Continuity and Access - Care providers can refer members to in-network specialists or connect them to Teladoc Health programs, facilitating care continuity and access to resources such as diabetes, hypertension, and weight management programs [7] - Real-time access to patients' pharmacy benefits enables care providers to identify covered drugs, copay amounts, and preferred alternatives, improving medication adherence and member satisfaction [8] Company Positioning - Teladoc Health has been delivering 24/7 Care virtual visits for over 20 years, with more than 100 million Americans having access to at least one of its services through health plans or employers, positioning the company as a leader in transforming virtual urgent care into a catalyst for better health and cost savings [9][12]

Core Viewpoint - LifeMD, Inc. has successfully closed a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability to support its growth initiatives and enhance financial flexibility [1][2]. Financial Details - The revolving credit facility has a maturity date of January 2, 2029, with $30 million of committed availability and an accordion option of up to $20 million [1]. - As of the closing date, LifeMD has not drawn any balance on the facility, indicating sufficient cash on hand and expected cash flow for its organic growth [1]. - The loans under the facility will bear interest based on either Term SOFR plus a spread of 150 to 225 basis points or the Alternate Base Rate plus a spread of 50 to 125 basis points [3]. - Fees on the committed unused portion of the facility range from 0.225% to 0.30%, depending on leverage, and there is no upfront fee for LifeMD [3]. Company Overview - LifeMD is a leading provider of virtual primary care and pharmacy services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [4]. - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [4].

Core Insights - Earth Science Tech, Inc. has engaged Hayden IR to enhance its investor relations and market awareness initiatives, following the successful completion of its FINRA 15c-211 clearance, which supports the company's strategy to scale its businesses into cash-generating entities [1][2] Company Overview - Earth Science Tech operates as a strategic holding company focused on value creation through the acquisition and management of its subsidiaries, which include compounding pharmaceuticals, telemedicine, and real estate development [5][10] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each contributing to its diversified business model [5][10] Financial Performance - In the first half of fiscal 2026, Earth Science Tech reported revenues of $17.8 million, net income of $1.4 million, and operating cash flow of $1.18 million, with gross margins exceeding 70% [3] - The company is noted to have significant operating leverage, indicating potential for higher earnings with rationalized expenses [3] Strategic Initiatives - The partnership with Hayden IR aims to develop a comprehensive investor relations program, focusing on clear communication of the company's strategy, performance, and long-term value proposition [2] - Hayden IR will assist in outreach to both institutional and retail investors, corporate access initiatives, and support for public disclosures and market education [2] Market Positioning - The CEO of Earth Science Tech emphasizes the importance of clearly communicating the company's current operations and growth strategy to the investment community as it enters a critical phase of market repositioning [2]

Core Viewpoint - Teladoc Health has experienced a significant decline in stock value, down nearly 92% over the past six years, and is unlikely to recover soon, making it a risky investment choice [1][2]. Group 1: Competition - The pandemic success of Teladoc attracted substantial competition, including from major corporations like Amazon, which has a strong brand and a large customer base [4][5]. - Other companies, including insurance firms, are also entering the telemedicine space, posing further threats to Teladoc's market position [5]. Group 2: Growth Drivers - Teladoc's virtual mental health service, BetterHelp, which was a key growth driver, has been struggling and is now a burden on revenue growth, losing paying members [6]. - Despite attempts to turn around its fortunes through international expansion, the company may face similar challenges abroad as it has in the U.S. [8][9]. Group 3: Financial Performance - Teladoc has not yet achieved profitability, and its sales growth has been slow or nonexistent, leading to a loss of market share [7][8]. - The company has a market capitalization of $1.3 billion, with a gross margin of 55.61%, but consistent net losses raise concerns about its financial health [7].

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...

As filed with the Securities and Exchange Commission on December 29, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VSEE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8000 86-2970927 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 980 N Federal Hwy Suite ...

Core Viewpoint - Mangoceuticals, Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $2.5 million to support its health and wellness product development and operations [1][3]. Group 1: Offering Details - The transactions involved the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant to purchase one share of Common Stock at an exercise price of $1.4245 [2]. - The offering price per Common Unit was set at $1.295, while the Pre-Funded Unit was priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Aspects - Aegis Capital Corp. served as the exclusive placement agent for the offerings, and the registered direct offering was conducted under an effective shelf registration statement previously filed with the SEC [4]. - The securities sold in the private placement were not registered under the Securities Act and were offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing a range of men's health and wellness products through a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7].

Core Insights - The company has announced a $100 million Solana-focused digital asset treasury strategy in partnership with Cube Group, aiming to leverage high-yield opportunities for sustainable growth [1][2][11] Group 1: Strategic Initiatives - The initiative positions the company at the forefront of institutional adoption within the Solana ecosystem, focusing on optimized entry points for long-term value creation [2][12] - The strategy is led by Cube Group, which has a proven track record in digital asset treasuries, and will manage custody, execution, and overall strategy for the company [3][4] - The company has filed a trademark application for "MULTI-DAT," indicating its strategic expansion into the digital asset sector, allowing for various financial activities including virtual currency transactions and investment portfolio oversight [5] Group 2: Digital Asset Treasury 2.0 Strategy - The strategy includes evaluating corporate treasury allocations into established digital assets to diversify holdings and enhance balance-sheet efficiency [8] - It explores participation in tokenized real-world assets to gain liquidity and transparency in a regulated environment [8] - The company plans to integrate regulated stablecoins for treasury management and cross-border activities, aiming to streamline operations and advance its core business [8] Group 3: Yield and Growth Model - The strategy aims for annualized SOL staking yields of 7-8%, with active management targeting yields of 8-20% [16] - The company emphasizes a non-dilutive growth model, utilizing Solana's staking mechanisms to enhance shareholder value without diluting existing shares [9][10] - The initiative is designed to generate superior risk-adjusted returns and contribute to the broader adoption of digital assets in mainstream finance [12]

Core Viewpoint - Mangoceuticals, Inc. has entered into agreements for a registered direct offering and a concurrent private placement, expecting to raise approximately $2.5 million in gross proceeds [1][3]. Group 1: Offering Details - The transactions involve the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant at an exercise price of $1.4245 [2]. - The offering price per Common Unit is set at $1.295, while the Pre-Funded Unit is priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Information - Aegis Capital Corp. is the exclusive placement agent for the offerings, and Lucosky Brookman LLP is acting as counsel to the Company [4]. - The registered direct offering is made under an effective shelf registration statement previously filed with the SEC [4]. - The securities in the private placement are not registered under the Securities Act and are offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing health and wellness products via a secure telemedicine platform, particularly in men's health sectors such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [8]. - The telemedicine platform allows consumers to request prescriptions, which are reviewed by a physician and fulfilled through a partner compounding pharmacy [9].

Core Insights - Earth Science Tech, Inc. (ETST) has received clearance from the Financial Industry Regulatory Authority (FINRA) for its Form 211 application, allowing for the initiation of priced quotations for its securities [1][2][3] Company Overview - ETST operates as a strategic holding company focused on acquiring and scaling high-potential operating businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through various subsidiaries [3] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, Earth Science Foundation, Las Villas Health Care, and an 80% interest in MagneChef [3] Subsidiary Highlights - **RxCompoundStore.com, LLC**: A fully licensed compounding pharmacy operating in multiple states, actively pursuing licensure in remaining U.S. states [4] - **Mister Meds, LLC**: A compounding pharmacy in Texas with advanced sterile compounding capabilities, applying for licensure in additional states [5] - **Peaks Curative, LLC**: A telemedicine platform offering consultations for compounded medications, expanding into the veterinary market through the acquisition of Zoolzy.com [6] - **Las Villas Health Care, Inc.**: A healthcare facility focused on the Spanish-speaking community, providing advanced health treatments [8] - **Avenvi, LLC**: A diversified real estate company managing a $10 million share repurchase program and overseeing investment activities for ETST [9] - **MagneChef**: A direct-to-consumer retail brand developing new cooking products and expanding into the BBQ tool market through the acquisition of BBQraft [9] - **Earth Science Foundation, Inc.**: A nonprofit organization providing financial support for prescription costs at ETST's pharmacies [10] Strategic Importance - The clearance of Form 211 is viewed as a critical milestone for ETST, expected to enhance shareholder value, improve liquidity, and provide greater visibility for executing its business plan [3]